ICM
SAGE

IronBridge Capital Management’s Sage Therapeutics SAGE Stock Holding History

IronBridge Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$3.57M Buy
+50,280
New +$2.95M 0.22% 141

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IronBridge Capital Management's SAGE Position: Q1 2017 in Review

IronBridge Capital Management opened a new position in Sage Therapeutics (SAGE) in Q1 2017: 50,280 shares worth $3.57M. The stake represents 0.22% of the portfolio and ranks #141 among its holdings.

190 funds tracked by Wall St. Rank hold SAGE as of Q1 2017.

  • IronBridge Capital Management held 50,280 shares of Sage Therapeutics worth $3.57M as of Q1 2017.
  • Sage Therapeutics was a new IronBridge Capital Management position in Q1 2017.
  • Sage Therapeutics made up 0.22% of IronBridge Capital Management's portfolio in Q1 2017, its #141 holding.
  • 190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2017.

Based on IronBridge Capital Management's 13F filing for Q1 2017, filed 10 May 2017.